Oxford Genetics, a leader in innovative synthetic biology-based technologies, has established a new agreement with clinical-stage gene therapy company, MeiraGTx. The collaboration will enable Oxford Genetics and London-based MeiraGTx to develop novel adeno-associated virus (AAV) vectors, as well as packaging and producer cell lines.
Dr Ryan Cawood, CEO at Oxford Genetics, said: “We are delighted to be working alongside the MeiraGTx team on such an exciting project, which will take us another step forward in our vision to deliver breakthrough technologies to the biotherapeutic industry.
“By creating advanced AAV production systems we aim to power the expansion of gene therapy as it moves towards addressing the more common disease indications that present technologies cannot satisfy.”
Dr Paul Brooks, CCO at Oxford Genetics, added: “The agreement further demonstrates that our business model for early access to our technologies is resonating with the biotherapeutic industry. Through such partnerships we will ultimately deliver real benefits to patients by helping our partners reduce therapeutic development time and achieving earlier market approval.”
Gloucester-based Mears Group, a leading provider of services to the UK Housing sector, has confirmed…
A consortium of mechanical and civil engineering, and robotic automation industry leaders, including Tunnel Engineering…
The market for technology isn’t working, according to the Chief Technology Officer of the National…
A leading UK industrial products supplier is expanding its UK fasteners division in Longborough, Gloucestershire,…
By Ian Mean, Business West Gloucestershire director Here in Gloucestershire, many farmers are really on…
South West and West Midlands housing association Bromford has announced another year of strong financial…